
Pauline Harper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2837424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. New England Journal of Medicine, 2020, 382, 2289-2301.	13.9	350
2	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine, 2019, 380, 549-558.	13.9	194
3	Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. Journal of Hepatology, 2016, 65, 776-783.	1.8	119
4	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology, 2020, 71, 1546-1558.	3.6	103
5	Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Current Treatment Options in Gastroenterology, 2007, 10, 444-455.	0.3	33
6	Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. Journal of Internal Medicine, 2022, 291, 824-836.	2.7	26
7	Management of acute intermittent porphyria. Expert Opinion on Orphan Drugs, 2014, 2, 349-368.	0.5	22
8	A Drugâ€Ðrug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Clinical Pharmacology and Therapeutics, 2021, 110, 1250-1260.	2.3	17
9	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. Genetics in Medicine, 2019, 21, 2605-2613.	1.1	16
10	RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. Journal of Internal Medicine, 2022, 291, 593-610.	2.7	11
11	Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report. Clinical Case Reports (discontinued), 2020, 8, 2483-2487.	0.2	5
12	Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria. Journal of Proteomics, 2015, 127, 377-385.	1.2	3
13	Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. Blood, 2016, 128, 2318-2318.	0.6	3
14	Liver Transplantation in Acute Hepatic Porphyria and Erythropoietic Protoporphyria. Handbook of Porphyrin Science, 2013, , 329-367.	0.3	0